Becton Dickinson and Co banner

Becton Dickinson and Co
NYSE:BDX

Watchlist Manager
Becton Dickinson and Co Logo
Becton Dickinson and Co
NYSE:BDX
Watchlist
Price: 149.31 USD 0.18% Market Closed
Market Cap: $42.5B

P/FCFE

17.6
Current
34%
Cheaper
vs 3-y average of 26.7

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
17.6
=
Market Cap
$52.1B
/
Free Cash Flow to Equity
$2.4B

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
17.6
=
Market Cap
$52.1B
/
Free Cash Flow to Equity
$2.4B

Valuation Scenarios

Becton Dickinson and Co is trading below its 3-year average

If P/FCFE returns to its 3-Year Average (26.7), the stock would be worth $226.49 (52% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+62%
Average Upside
40%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 17.6 $149.31
0%
3-Year Average 26.7 $226.49
+52%
5-Year Average 28.6 $242.2
+62%
Industry Average 21.8 $184.91
+24%
Country Average 21.9 $185.33
+24%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
US
Becton Dickinson and Co
NYSE:BDX
42.5B USD 17.6 24.2
US
Intuitive Surgical Inc
NASDAQ:ISRG
162.6B USD 65.3 56.9
US
Abbott Laboratories
NYSE:ABT
155.4B USD 29 24.8
US
Stryker Corp
NYSE:SYK
112.7B USD 20.7 34.7
IE
Medtronic PLC
NYSE:MDT
102.7B USD 27.3 22.3
US
Boston Scientific Corp
NYSE:BSX
83.8B USD 29.3 23.5
US
Edwards Lifesciences Corp
NYSE:EW
48.8B USD 37 44.5
DE
Siemens Healthineers AG
XETRA:SHL
39.3B EUR 41.4 18.6
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.2B USD 46 42.7
US
Resmed Inc
NYSE:RMD
29.9B USD 17.2 20.1
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
204.2B CNY 25.9 26.1

Market Distribution

In line with most companies in the United States of America
Percentile
41th
Based on 7 576 companies
41th percentile
17.6
Low
0 — 13.1
Typical Range
13.1 — 36.5
High
36.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.1
Median 21.9
70th Percentile 36.5
Max 3 188 432.5

Becton Dickinson and Co
Glance View

Founded in 1897, Becton Dickinson and Co., commonly known as BD, embarked on its journey with the vision to improve medical discovery and diagnostics. Over the decades, BD has transformed from a small syringe and needle manufacturer to a global leader in the medical technology industry. Situated in Franklin Lakes, New Jersey, BD has carved out a prominent place through its steadfast commitment to addressing health care workers' requirements and enhancing patient outcomes. The company's diversified portfolio spans across three major segments: BD Medical, BD Life Sciences, and BD Interventional. This trinity of divisions underscores BD's prowess in producing a broad range of medical supplies, laboratory equipment, and diagnostic products that find their way into hospitals, research facilities, and clinics worldwide. The company operates primarily by innovating and supplying products that are indispensable to everyday medical care and scientific research. BD’s robust revenue stream is bolstered by its strategic approach to integrating new technologies and acquiring innovative smaller companies that complement its core offerings. Through strategies like these, BD continuously adapts to the evolving healthcare landscape. Its products, such as advanced syringes, safety-engineered devices, and sophisticated laboratory equipment, are deeply embedded in the healthcare system, making BD a critical part of the global push for improved health outcomes. The company’s blend of consistent product demand and strategic innovations secures a stable financial footing, allowing it to invest further in research and development while extending its market reach across the globe.

BDX Intrinsic Value
228.74 USD
Undervaluation 35%
Intrinsic Value
Price $149.31
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett